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The European General Data Protection Regulation: Challenges and Considerations 
for iPSC Researchers and Biobanks 
 
Abstract:  
Increasingly, human induced pluripotent cells (iPSC) and their associated genetic and 
clinical information are being used in a wide range of applications, with large biobanks 
being established to support and increase their scientific use. The new European 
General Data Protection Regulations (GDPR), which comes into effect in 2018, will 
have implications for biobanks that generate, store and allow research access to iPSC. 
This paper describes some of the challenges that face iPSC biobanks and suggests 
some points for the development of appropriate governance structures to address 
these new requirements. These suggestions also have implications for iPSC research 
in general.  
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Introduction 
It was only a decade ago that the first report of cell reprogramming to produce an 
‘embryonic cell-like state’ using cells from adults, rather than the more socially 
controversial embryos, was reported [1]. Since then, the technology to create these 
induced pluripotent stem cells (iPSC) has become more widely used, and the 
technique has been incorporated into a range of major translational applications [2]. 
Human iPSC are currently being investigated as a source of cells for regenerative 
medicine [3], as tools for in vitro modelling of human development and disease, and 
for cell-based assays of small molecule drug candidates [4], [5] [6]. In these latter 
applications, iPSC are viewed as especially valuable because they can be derived 
from adults or children who have  particular conditions, enabling  disease-specific cell 
lines to be created, or from healthy volunteers to generate well-defined control lines. 
A number of high-profile endeavours – the European Bank for induced pluripotent 
Stem Cells (EBiSC), the Stem Cells for Biological Assays of Novel drugs and 
prediCtive toxiCology consortium (StemBANCC), the New York Stem Cell Foundation 
(NYSCF) Stem Cell Bank, and the Human induced pluripotent Stem cell initiative 
(HipSci) – are working to produce, bank, and disseminate human iPSCs to support 
further investigation of these translational applications [7], [8], [9] [10]. 
Unlike human embryonic stem cells (hESC), human iPSC usually originate from 
individuals from whom additional phenotypic, clinical, and behavioural data (such as 
family history, age of disease onset, medications, diagnostic results etc. [11]) may be 
accessed. Unless the iPSC are derived from foetal tissue or a deceased donor, these 
individuals are ‘natural or legal persons’ and the data are ‘personal’ and ‘health’ data, 
which are considered especially sensitive and deserving of legal protection. All 
personal data are regulated by data protection law, meaning donors are entitled to a 
high degree of privacy protection and to security of the data associated with the cell 
line.  
 European data protection law is set to change. In May 2018, the current 
European Data Protection Directive (Directive 95/46/EC) [12] will be replaced with the 
new General Data Protection Regulation (GDPR, or Regulation) [13]. The scope of the 
GDPR includes ‘pseudonymised data’; where the sample donor is de-identified, but a 
key that allows a connection to the original tissue donor to be made is maintained.  
Data protection changes will apply whether iPSC are derived from ‘new’ donated 
material or existing tissue samples that are not fully anonymous. Projects based in 
European countries, including EBiSC, StemBANCC and HipSci, are required by 
European laws on the traceability of biological material to pseudonymise rather than 
anonymise data and samples so their operations automatically come under the scope 
of the new Regulation. An example traceability system implementing 
pseudonymisation for hiPSC biobanking is described in [14]. All of this means that 
existing arrangements in place for sharing hESC lines and associated data, including 
SNP genotyping [15], are not automatically adequate and appropriate for 
disseminating well-characterised iPSC lines.  
Given the imminence of the GDPR – which strengthens a regime already 
considered one of the most stringent in the world [16] – it is timely and appropriate to 
review the data protection implications of making iPSC and associated genetic and 
clinical data available to the global scientific community. The aim of this paper is to 
offer some preliminary views on the impact of changing data protection law for iPSC 
researchers and iPSC-based biobanks. First, we identify some of the core features of 
the GDPR. Second, we identify key matters for consideration when designing 
governance arrangements for iPSC biobanks. Third, drawing on the standards 
articulated in the GDPR, we offer some recommendations, based on our collective 
experience in the biobank setting, as to how to proceed. 
 
The General Data Protection Regulation 
The GDPR updates existing European data protection law, replacing European Union 
(EU) Directive 95/46/EC on data protection. The major differences between the 
Regulation and existing European data protection law are summarised in Box 1. 
 
Box 1: Main changes resulting from the replacement of Directive 95/46/EC with the 
General Data Protection Regulation 
i. Higher fines for firms contravening the new Regulations based on global 
turnover;  
ii. New requirements for organisations to appoint a Data Protection Officer if the 
organisation handles ‘significant’ amounts of sensitive data. 
iii. Genetic data is now explicitly recognised as ‘sensitive personal data’.  
iv. ‘Privacy by design’ approach to data protection strongly advocated, with data 
protection safeguards to be built into organisations’ products and services 
from the earliest stage of development and ‘privacy-friendly’ techniques such 
as pseudonymisation, encryption and anonymisation promoted.  
v. New direct obligations on data processors, including maintaining certain 
records of all processing activities and taking appropriate security measures 
to protect personal data. 
vi. Expanded territorial reach as the GDPR places obligations on non-EU 
organisations who process or monitor data of EU citizens. 
vii. Broad consent for scientific research is specifically allowed  although more 
specific consent options should be offered if compatible with the research. 
viii. Data being used for research is exempt from some of the new data subject 
rights such as the right to be forgotten and the right to object to processing of 
ones’ data, but must be collected and stored subject to appropriate 
safeguards enforcing the principle of data minimisation. 
ix. Whereas some national interpretations of the Directive allowed data being 
used for research to be stored indefinitely, the Regulation stipulates research 
data should be stored ‘for as long as necessary’. 
 
 
 Under the terms of the Directive, European Member States were entitled to 
implement data protection requirements into national law in ways that allowed for 
differences between the jurisdictions states [17]. The Regulation, by contrast, should 
be directly transposed into the national laws of EU Member States, in principle 
producing harmonisation of European data protection legislation. However, the GDPR 
does allow for some national variations (derogations) in certain circumstances [18] so 
it is likely that some differences between Member States will persist after 2018. For 
example, each state can set a minimum age for consent to use of data at between 13 
to 16 years of age. Prior to implementation the extent and impact of national variations 
cannot be known, but this is an area that will require further monitoring. The UK 
government has confirmed, through its Information Commissioner’s Office (ICO), that 
it will also implement the GDPR despite the decision to exit from the European Union. 
[18]. Therefore, the GDPR will apply uniformly to all researchers, biobanks and 
institutions using iPSC cells located within Europe.  
 Key aims of the GDPR, articulated in Recitals 7, 9, 10 and 11, and Article 1, 
are described in Box 2:Box 2: Key aims of the General Data Protection Regulation 
 Ensure a consistent and high level of protection of natural persons while also 
removing the obstacles to flows of personal data within the EU. 
 Harmonise the level of protection of the rights and freedoms of natural 
persons with regard to the processing of such data across the EU.  
 Clarify the obligations of data processors and ensure strong enforcement. 
 
The pursuit of these aims is guided by the fair processing principles set out in Article 
2 of the GDPR and described in Box 3: 
Box 3: Fair Processing Principles set out in the General Data Protection Regulation 
 The purposes for processing must be legitimate, specified, and limited. 
 The processing practices must be lawful, fair and transparent. 
 They must involve appropriate security to safeguard privacy and data 
integrity. 
 The data must be adequate, relevant, and limited (data minimisation), and 
must be accurate and maintained as identifiable only for as long as is 
necessary given the purposes of collection. 
 
In all cases, data controllers have primary responsibility, and will be held accountable 
for ensuring compliance. Given the tenor of the GDPR, we can assume that data 
controllers (here universities, hospitals and companies operating a biobank or 
processing large amounts of personal data for other research purposes) will be 
expected to meet fairly strict standards when it comes to receiving, holding and 
distributing (processing) cell-lines and associated data.  
However, EU law is guided by the principle of proportionality [20] which allows 
the application of the law to be adapted to particular circumstances, in this instance 
biobanking. Article 24 of the Regulation states that, taking into account the nature, 
scope, context and purposes of processing, as well as the likelihood of breaches or 
failures, and the severity of harms resulting therefrom, controllers shall implement 
appropriate technical and organisational measures. Article 25 acknowledges context 
and cost implications of decision-making when designing data protection measures.  
Biobanks may also be exempt from a number of provisions of the GDPR, in particular 
under exemptions provided to permit the processing of personal data for purposes of 
scientific research. Such provisions allow personal data to be stored for longer periods 
than would otherwise be permitted, provided that i) they will be processed solely for 
scientific research purposes in accordance with GDPR Article 89(1), and ii) that the 
data will be subject to implementation of technical and organisational measures 
required by the GDPR. The Regulation also retains a presumption of ‘compatibility of 
use for research purposes’, which allows personal data collected for purposes other 
than scientific research to be repurposed for research as long as there is a valid legal 
ground for the original processing in EU or Member State law. Finally, universities may 
be exempt from the requirement to protect some of the rights of data subjects accorded 
in the Regulation, where to exercise these rights would prevent or seriously impair the 
possibility of the research being carried out.  
A number of provisions of the GDPR apply to anyone who generates human-
derived iPSC and associated data, and/or wishes to bank and distribute them. The 
Regulation also applies to anyone who wishes to work with data derived from EU 
citizens, whether or not the data user (processor) is itself based in the EU. The GDPR 
is therefore relevant for anyone using human data, including scientists and biobank 
managers, in both EU and non-EU jurisdictions. For some of the key terms, as they 
are defined in the GDPR, and their relevance to iPSC banking, see Table 1.  
 
Table 1: Key terms in the General Data Protection Regulation (GDPR) and their 
relevance to iPSC banking 
Term Meaning in the GDPR Relevance to iPSC Research 
Data 
subject 
An identifiable natural person who can be 
identified, directly or indirectly, especially 
by reference to an identifier such as a 
name, an identification number, location 
data, an online identifier or to one or more 
factors specific to the physical, 
physiological, genetic, mental, economic, 
cultural or social identity of that natural 
person. 
European regulations on the traceability 
of biological material [21] [22], mean 
that, for quality and safety purposes, all 
iPSC derived from new samples must be 
traceable to the sample donor. This 
means that data associated with iPSC 
and derived from them can be 
pseudonymised but must not be fully 
anonymised. IPSC derived from new or 
existing samples where the sample 
donor is not fully anonymised therefore 
relate to identifiable legal/natural 
persons and so fall within the scope of 
the GDPR. This requirement is mirrored 
by World Health Organisation guidelines 
on traceability of human organs, tissues 
and cells [23] meaning 
pseudonymisation is also recommended 
practice outside the European Union 
(EU). 
Data 
processing 
Any operations which are performed on 
personal data or sets of personal data, 
whether or not by automated means, such 
as collection, recording, organisation, 
structuring, storage, adaptation or 
alteration, retrieval, consultation, use, 
disclosure, dissemination or otherwise 
making available, alignment or 
combination, restriction, erasure or 
destruction. 
Collection, storage, editing, analysing or 
otherwise working with genetic or patient 
data associated with an iPSC line counts 
as data processing. 
Data 
processor 
A natural or legal person, public authority, 
agency or other body which processes 
personal data. 
Any researcher or entity that collects, 
stores, edits, analyses or otherwise 
works with genetic or patient data 
associated with an iPSC line counts as a 
data processor. 
Data 
controller 
The natural or legal person, public 
authority, agency or other body which, 
alone or jointly with others, determines the 
purposes and means of the processing of 
personal data. 
Any institution, such as a university, that 
runs a biobank or employs scientists 
who work with personal data (including 
pseudonymised data associated with 
iPSC or other cell lines) counts as a data 
controller. 
Supervisory 
Authority 
An independent public authority in each EU 
Member State tasked with the responsibility 
of monitoring and enforcing the correct 
application of the Regulation. All countries 
signed up to the GDPR must nominate a 
Supervisory Authority. Some states may 
Data controllers and data processors 
who work with iPSC are ultimately 
responsible to the Supervisory Authority 
for their handling of sensitive personal 
information associated with, or derived 
from, the cell lines. Supervisory 
choose to split different areas of this 
responsibility between two or more public 
bodies.  
Authorities are also involved in 
monitoring cross-border flows of data 
and can require that data not be 
provided to a specified non-EU country. 
Data 
Protection 
Officer 
An individual appointed by an institution 
involved in processing personal data on a 
large scale to oversee compliance with 
data protection law. 
A DPO would be able to help biobanks, 
as well as academic or commercial 
scientists working with iPSC, to meet 
their data protection obligations. 
Personal 
data 
Any information relating to an identified or 
identifiable natural person (data subject).  
Fully anonymised data do not count as 
personal data. Pseudonymised data are 
re-identifiable and so count as personal 
data caught by the GDPR.  
Data 
concerning 
health  
Personal data related to the physical or 
mental health of a natural person, including 
the provision of health care services, which 
reveal information about his or her health 
status. 
All three categories of data are 
considered especially sensitive, 
warranting a higher level of protection 
than other types of information. Data 
concerning health and/or biometric data 
may accompany iPSC derived from 
patients or healthy volunteers. Some 
element of genetic data is also likely to 
be provided with the iPSC line to 
characterise it, or will be derived from the 
biological sample by recipients of the cell 
line. Once genetic information is 
extracted from the sample, even if it is 
not whole genome/exome sequence 
data, it becomes subject to data 
protection law. 
Genetic 
data  
Personal data relating to the inherited or 
acquired genetic characteristics of a natural 
person which give unique information 
about the physiology or health of that 
natural person and which result, in 
particular, from an analysis of a biological 
sample from the natural person. 
Biometric 
data 
Personal data resulting from specific 
technical processing relating to the 
physical, physiological or behavioural 
characteristics of a natural person, which 
allow or confirm the unique identification of 
that natural person, such as facial images 
or fingerprint data. 
 
The GDPR and Key Operational Matters 
As compliance with data protection law is a function of biobank governance, it 
implicates a number of matters, which are simultaneously operational, legal and in 
some cases ethical in nature. Here we highlight several such matters for which the 
GDPR has particular relevance. 
 
Consent 
Consent is the most common mechanism by which we enable individuals to exercise 
their autonomy in relation to medical research, though its limits in terms of practice 
must be acknowledged. The GDPR requires a legal basis for processing personal data 
and consent is one such legal basis. Consent must be obtained before personal 
information about an individual (a data subject) can be collected and processed 
(Article 7). It is mandated that consent should be informed and explicit. This applies to 
consent provided by an individual participant, or by a proxy on behalf of someone who 
is not capable of giving valid consent (e.g. for collection of samples from paediatric 
cohorts or patients with dementia). The provisions for research make it clear that the 
use of a broad consent, where participants agree that their samples and data can be 
made available, subject to a suitable governance framework being in place, is 
permissible in biobanking research. The requirement to be explicit about what is being 
consented to, however, has implications for how consent is presented and collected 
in projects or biobanks recruiting iPSC donors. At minimum, consent forms should 
contain separate statements (to be individually signed/initialled by the participant) 
reflecting agreement that a biological sample can be collected, can be reprogrammed, 
can be stored, and can be shared together with the personal and/or medical data of 
the participant. When proposing to derive human iPSC from tissue samples that were 
obtained previously in support of a research plan that did not include iPSC derivation, 
then the validity of the existing consent for this new purpose will need to be reviewed 
by an appropriate body such as a biobank governance board or a research ethics 
committee [24].  
Genetic and biometric data can be considered ‘inherently identifying’ because 
they relate to a particular individual. The GDPR imposes a general prohibition on 
processing of data wherever identification of an individual data subject is possible, 
unless explicit consent has been given (Article 9). It is therefore advisable to seek 
explicit consent for the collection and processing of genetic or biometric data, and 
researchers should avoid giving tissue donors a guarantee of absolute anonymity or 
privacy. To promise that the donor cannot and will never be identified is to encourage 
an unrealistic expectation, and could expose researchers to liability if a data subject is 
identified (e.g. through a data breach) [11], [25]. Academic studies that generate iPSC 
should also consider the consent requirements associated with making these cell lines 
available to the wider research community. It is important to be clear about how the 
data will be used and distributed, so recruiters should ensure that participants give 
permission to share cell lines and data with researchers in other countries, the private 
sector, and consent to post-study deposition of the lines and data in a biobank such 
as EBiSC. 
 
Record Keeping and Accountability 
The principles of accountability and transparency have been strengthened by the 
GDPR and are now central to data protection. These principles have increased the 
administrative responsibilities of data processors and controllers, who must now 
ensure that they have effective governance mechanisms in place. They must be able 
to demonstrate compliance both internally, and externally, to the relevant Supervisory 
Authority, which, in the case of England and Wales, is the ICO. Where more than one 
EU country is involved in a project, there will be an agreed lead supervisory authority. 
Importantly, the GDPR imposes, for the first time, direct responsibilities and penalties 
on data processors, in addition to data controllers. Under Articles 28 and 30, 
processors are required to maintain records of processing activities, and to take 
appropriate security measures to protect personal data ‘to ensure a level of security 
appropriate to the risk’. 
Under the rubric of transparency and accountability, Article 30 stipulates that 
data controllers must keep the records listed in Box 4: 
Box 4: Updated record keeping requirements for data controllers 
a. name and contact details of the controller; 
b. purposes of the processing; 
c. description of categories of data subjects and personal data; 
d. categories of recipients to whom personal data have been, or will be, 
disclosed, including in third countries or international organisations; 
e. transfers of personal data to a third country or international organisations; 
f. where possible, envisaged time limits for erasure of the different categories 
of data; and 
g. where possible, a general description of the technical and organisational 
security measures referred to in Art 32(1).  
 
 
Biobanks and researchers using standard information management tools, such as a 
Laboratory Information Management System (LIMS), commonly maintain records of 
the location of all biobank samples/stock, and the period of time they are expected to 
be held there.  The GDPR– particularly Article 30(d) and (e) – suggests t further 
records, concerning origin of data associated with each cell line (source, collection 
time, institutional or individual collector) may also need to be kept. These standards 
would apply to online catalogues and systems like the Human Pluripotent Stem Cell 
Registry [26] and the Stem Cell Database [27]. 
Another GDPR requirement is that controllers and processors must keep 
records up to date (Article 30). In addition to being an explicit rule, this requirement for 
stable and durable linkages is a sensible practice relevant to the longevity of the iPSC 
as a communal resource. Under this rule, biobanks and iPSC researchers who 
generate cell lines and collect clinical data must find ways to ensure a long-term, stable 
means of access to the pseudonymisation key that links individual donors and their 
samples/data. If this is left to individual scientists, clinicians, managers or hospital staff 
who have had personal contact with the biobank, for example as material or data 
depositors, these connections are likely to be lost as projects end, contact details 
change, and people move on over time.  
One way to achieve this stability and durability is suggested by Article 37(1) of 
the GDPR, which obliges institutions processing sensitive and personal data on a 
large-scale to appoint a Data Protection Officer (DPO), whose task it is to assist the 
monitoring of internal compliance with the GDPR. Given the nature of biobanks like 
EBiSC and NYSCF, and the large numbers of iPSC intended for production and 
dissemination by them, the appointment of a DPO is a reasonable and pragmatic 
undertaking [28]. For biobanks and research groups who produce and share human 
iPSC, part of the role of the DPO could be to serve as custodian for the 
pseudonymisation keys, and to act as a contact point for traceability and re-contact 
requests. Although organisations with less than 250 employees are exempt from the 
obligation to appoint a DPO, it should be noted that from the perspective of a biobank, 
the organisation in question may be a larger entity within which the bank is situated; 
in other words, if the biobank is housed in or associated with a hospital or university, 
the number of employees for regulatory purposes will be that of the broader hospital 
or university [29].  
 
Data Minimisation 
The principle of data minimisation is strongly embedded in the GDPR. Article 5(1)(c) 
states that personal data shall be ‘adequate, relevant and limited to what is necessary 
in relation to the purposes for which they are processed (‘data minimisation’)’. The 
importance of this principle to the new regime is indicated by its reinforcement in both 
Article 25, which addresses data protection by design, and Article 89(1), which 
addresses safeguards and derogations where data are used specifically for research.  
The practical achievement [30], and indeed the propriety of the pursuit, of data 
minimisation present challenges in the biobank setting. The notion of a quantitative 
restriction that prohibits collection of more data than are strictly necessary for the task 
at hand is a concept inherently problematic for all scientific research, but particularly 
for undertakings that aim to generate resources for presently unanticipated future 
investigations. Increasingly, funding bodies and publishers are requiring researchers 
and research institutions to share their data as a criterion of receipt of funding or 
publication of results [31]. Further, the key aim of accessibility held by large iPSC 
banks, which would make iPS cells and data ‘maximally available’ to as many 
scientists as possible, also seems at odds with this principle, insofar as it means 
keeping the amount of processing and the number of processors to a minimum.  
At present, it is recommended that biobanks take steps to ensure that the data 
they collect are related to the purposes ‘for which they are processed’, which will be 
primarily research (broadly conceived) and that this is appropriately communicated in 
the consent process.. For example, samples and data from patients with 
neurodegenerative disease might reasonably include data on age of onset, as this is 
clinically relevant to the research topic even though this information will not necessarily 
be utilised in every research project involving the samples. Scientists and biobanks 
should also de-identify the data to the extent that this does not interfere with research 
objectives. It is also advisable that those biobanks that collect samples and associated 
data for long term and uncertain future uses should review existing data protection 
provisions for relevance each time they plan a further data collection initiative, or when 
a significant amount of new data is added. Ethical oversight bodies, such as data 
access committees, research ethics committees and institutional review boards, 
should also be vigilant in considering whether particular requests for data access – for 
example to provide ‘all data’ on a particular data subject – warrant additional 
safeguards to ensure that the anonymity of the subject is secure.  
 
Transfer of Samples/Data Outside the EU 
International transfers of data to third countries or international organisations are a 
matter of significant uncertainty for biobanks intending to promote global access to 
their resources, and they hold an ambiguous position within the GDPR. Despite the 
Recital 101 affirmation that international flows of personal data are necessary for the 
expansion of trade and cooperation, Article 44 of the GDPR begins with a prohibition 
of such international transfers of personal data, on grounds that such movement of 
personal data may jeopardise both the ability of natural persons to protect themselves 
from unlawful use or disclosure of that information, and the ability of EU authorities to 
pursue complaints or conduct investigations relating to activities outside their borders. 
The primary exception to the prohibition, articulated in Article 45, is a 
Commission decision, with effect for the entire EU, that there is an ‘adequate level of 
protection’ of the fundamental rights of the data subject in the foreign jurisdiction (i.e., 
an opinion that the foreign protections are essentially equivalent to that ensured within 
the EU). Although an EU registry of data-friendly jurisdictions might ultimately increase 
the efficiency of iPSC dissemination, and promote harmonisation of global data 
protection, it is unlikely to provide an immediate avenue for validation of dissemination 
of cells and data by international iPSC biobanks. Commission decisions will take time, 
as they are made by means of an implementing act following an assessment that takes 
into account the legal environment, the existence and functioning of independent 
supervisory authorities, and international commitments of the foreign jurisdiction, 
particularly in relation to protection of personal data. 
The more pertinent question for biobanks may be whether standard Material 
Transfer Agreements, Codes of Conduct, or other mechanisms contemplated by the 
GDPR are capable of providing ‘appropriate safeguards’ for the legitimation of routine 
international transfers of data (Article 46). Some basis for proceeding is the existing 
‘model contract’ clauses for transfer of personal data outside the EU that were 
produced to help data controllers comply with the previous EU data protection 
Directive [32], [33]. In the absence of an adequacy decision by the Commission under 
Article 45.3, a controller or processor may transfer personal data to a third country or 
an international organisation only if: 1) the controller or processor has provided 
‘appropriate safeguards’; and 2) enforceable rights and effective legal remedies are 
available to data subjects. 
 Article 46(2) offers a list of ‘appropriate safeguards’ – including binding 
instruments between public authorities, binding corporate rules, standard data 
protection clauses adopted by the Commission or a Supervisory Authority, an 
approved code of conduct or certification mechanism – but each of these require the 
prior approval of the Commission or a relevant independent Supervisory Authority 
established under Chapter VI. Further, there is no instruction offered with respect to 
how to ascertain the availability of enforceable rights and effective remedies for data 
subjects in the foreign jurisdiction, or who is responsible for doing so. 
 
Conclusion 
International circulation of biologicals and associated data is considered essential for 
the advancement of basic research and clinical translation of stem cell science. 
Biobanks and registries for disseminating well-characterised induced pluripotent stem 
cells are an important part of this endeavour, but they also raise particular issues for 
data protection, as most iPSC are derived from individuals with data protection rights. 
The forthcoming European General Data Protection Regulation represents a change 
to the legal requirements for data protection. It is therefore important to communicate 
how these changes affect the responsibilities of biobanks, and researchers accessing 
biobanks, so that they can remain in compliance with the law during the course of their 
work. This is doubly relevant because the GDPR extends the legal reach of European 
law to any person or institution processing data derived from EU citizens, regardless 
as to where that person or institution is located [16].  
Some of these responsibilities can be dealt with relatively easily by putting in 
place data protection policies for projects, institutions, and consortia. Such policies 
might ensure, for example, that no sensitive data leaves a secure site unless it is 
stored on an encrypted device, or that contracts and legal agreements contain 
provisions requiring anyone with access to pseudonymised personal data to refrain 
from attempting to identify any data subject. Other elements of the GDPR look likely 
to increase the bureaucratic burden of sharing, at least on a large scale, human-
derived iPSC cells and data, and will require additional administrative support such as 
the appointment of specialist Data Protection Officers.  
The most challenging of the GDPR provisions are those in which the aims of 
the Regulation seem least aligned with those of biobanking: data minimisation and 
transfer of samples and data outside the EU. Data minimisation might be mitigated by 
a move towards enabling greater, even ongoing, contact with sample donors, allowing 
researchers to go back and collect additional data if, as, and when it is needed instead 
of treating data collection as a one-off event [34]. A move towards digital tools for 
consent and engagement may offset some of the administrative burden of sustained 
interaction [35] [36]. The issue of transfer of data outside the EU is potentially the most 
challenging development. It should be noted that ‘transfer’ outside the EU includes 
digital transfer of data via ‘cloud computing’ services, if the data is stored on a server 
that is located in a non-EU country. The Regulation transforms into a formal legal 
responsibility that which was previously an internal process: assessment by biobank 
staff of the legitimacy of a person or institution who requests access to a cell line and 
associated data [37]. This change is problematic because the responsibility will be 
conferred before the necessary range of decision-making tools (in the form of a 
registry of EU approved or prohibited data destinations) are made available and in this 
regard the only option seems to be to stick to current best practice for data transfer 
while pushing the Commission to clarify its adequacy decisions on relevant countries 
and seeking additional resources to deal with this requirement. 
 
In Table 2, we offer a list of key recommendations to assist biobanks and researchers 
who work with human-derived iPSC to comply with changing data protection law. 
 
Table 2: Summary data protection recommendations for iPSC biobanks  
Consent forms for recruiting donors of iPSC-originating tissue need to contain separate, explicit 
consent for donation of the biological sample for reprogramming and for the collection and 
processing of personal data and genetic data that will be used to characterise the cell line. 
A broad consent can be collected, but biobanks and researchers should still consider adding 
explicit consent provisions to allow iPSC lines and associated data to be made available to the 
wider scientific community, including commercial companies. 
Institutions need a long term plan for maintaining connections between pseudonymised data 
and sample donors. This connection needs to be durable and enable access from subsequent 
data controllers, even if the samples/data are produced by a fixed term project or consortium. 
Data controllers and processors need to be aware of their increased administrative 
responsibilities in order to ensure compliance with the record keeping requirements of the 
General Data Protection Regulation (GDPR)  accountability and transparency provisions. 
Data controllers should consider implementing a ‘privacy by design’ approach to all operations 
in order to meet privacy, security and data minimisation commitments.  
In order to comply with the principle of data minimisation, biobanks and scientists deriving 
human iPSC should ensure that collected data are related to the purpose for which they are 
processed i.e. research, broadly conceived. This should be reviewed if a significant tranche of 
additional data is collected. This may require putting in place mechanisms to recontact donors 
to update their data or provide additional information. 
Personal data on European Union (EU) citizens, including pseudonymised data, may only be 
transferred to data processors in non-EU countries if these have ‘adequate protection’ for data 
security in place. In the long term, the Commission is expected to rule on the data protection 
adequacy of various non-EU states, but in the short term data processors and controllers are 
advised to make use of formal contracts such as Material Transfer Agreements that employ 
standard data protection clauses of the kind provided on the EU and ICO websites.  
 
 
Future perspective 
Biobanks are important resources for translational research but they also face 
challenges to sustainability [38], [39]. It is likely that over time there will be first 
increasing collaboration between different iPSC banks driving harmonisation of 
standards, including those for data protection, and ultimately international networks of 
biobanks working to facilitate the international flow of cell lines and data across 
jurisdictions [40]. There is precedent in initiatives like Promoting Harmonization of 
Epidemiological Biobanks in Europe (PHOEBE) and the Biomolecular Resources 
Research Infrastructure - European Research Infrastructure Consortium (BBMRI-
ERIC).[41] Pluripotent stem cell banks founded in or after 2018 will need to be 
designed to be GDPR compliant from the outset. 
 
At the same time meeting quality, safety, data protection, traceability and other 
commitments takes considerable administration work and is likely to result in high 
running costs for hiPSC banks. To meet these costs cell banks may have to leverage 
the value of well characterised iPSC to the pharmaceutical industry through longer 
term engagement between public and private sectors.  
 
Failure to adequately address issues associated with data protection and related 
aspects of biobank governance run the risk of not only stifling research using iPSC but 
public trust and support for this important facet of biomedical research.  
 
Executive Summary 
This paper reviews the impact of changing data protection law for iPSC researchers 
and iPSC-based biobanks and offers recommendations on how to operate in ways 
that ensure compliance with the requirements of the forthcoming European General 
Data Protection Regulation 
The General Data Protection Regulation 
 The European General Data Protection Regulation (GDPR) comes into force in 
May 2018 and will apply in all EU Member States, in the UK, and to any transfer 
of data derived from EU citizens to territories outside the EU. 
 Its purpose is to harmonise the law regarding the protection of personal data 
and clarify the obligation of any persons working with personal data 
 Data related to health, biometric data, and genetic data can all be used to 
characterise human-derived induced pluripotent stem cells and all come under 
the scope of the Regulation if they are not fully anonymised. 
Consent 
 Consent forms should collect explicit consent for i) donation of biological 
sample for reprogramming, ii) collection of personal data, iii) collection of 
genetic and biometric data, and iv) sharing of sample and associated data  
 Academic studies which generate iPSC for the study of patients in a particular 
diagnostic category should also consider the consent requirements to allow 
these cell-lines to be deposited in a biobank for subsequent distribution 
Record Keeping and Accountability 
 Data controllers and data processors must keep adequate and up to date 
records of what data has been collected, stored and accessed. 
 Institutions processing sensitive and personal data on a large-scale to appoint 
a Data Protection Officer (DPO). This will include large biobanks, universities 
and companies with more than 250 employees. 
 It is also critically important to maintain robust institutional connections so that 
pseudonymised samples and data can be connected back to individual donors. 
Data Minimisation 
 The GDPR advocates minimising the amount of data collected and 
implementing privacy by design approaches to achieve this. 
 Both these objectives are challenging to achieve for biobanks dedicated to 
making samples and data ‘maximally available ‘ to the global research 
community 
Transfer of Samples/Data Outside the EU 
 The GDPR prohibits the transfer of personal data outside the EU unless the 
foreign jurisdiction is adjudged to have adequate data protection measures in 
place. 
 In the absence of a complete list of approved jurisdictions, the responsibility 
currently falls on the institution controlling the data to ensure that appropriate 
safeguards are in place. 
 Material Transfer Agreements, Codes of Conduct, and other agreements offer 
some measure of protection 
Discussion 
 A table of key data protection points for scientists and biobanks working with 
human derived iPSC to take in to account is provided. 
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